Spyre Therapeutics (SYRE) is trading higher as the market continues to digest the company’s April 13, 2026 topline update from Part A of the Phase 2 SKYLINE trial for SPY001 in moderate-to-severe ulcerative colitis. In that update, Spyre said SPY001 met the primary endpoint and delivered clinically meaningful secondary outcomes, helping extend a post-data rally that has drawn fresh momentum buyers. (sec.gov)

Spyre reported that SPY001 produced a statistically significant reduction in the Robarts Histopathology Index (RHI) score at Week 12 and highlighted rates of clinical remission and endoscopic improvement as key secondary outcomes. The company also said recruitment for SKYLINE Part A is closed and that additional proof-of-concept induction readouts for other cohorts are expected mid-2026 (SPY002) and in Q3 2026 (SPY003), keeping near-term catalyst focus elevated. (sec.gov)

Adding to the bullish tone, Spyre announced it closed its underwritten public offering on April 16, 2026, including full exercise of the underwriters’ option, for gross proceeds of $463.5 million. With the deal completed, some investors appear to be treating the financing as a balance-sheet de-risking event rather than a near-term dilution headline, supporting follow-through buying. (ir.spyre.com)

Traders are now likely to focus on whether the company can sustain clinical momentum with upcoming 2026 readouts and how quickly Spyre can translate SPY001’s initial induction signal into broader trial validation. Continued positive analyst revisions after the SKYLINE update have also helped keep attention on the name, and incremental upgrades/target hikes can amplify day-to-day price moves when momentum is strong. (ng.investing.com)